A Study In Patients With Advanced Solid Tumor

Pfizer

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: Axitinib (AG-013736)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00726752

A4061044

Details and patient eligibility

About

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

Enrollment: 6 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients histologically or cytologically diagnosed with advanced solid tumors
• Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
• Patients with no uncontrolled hypertension

Exclusion criteria

• Patients who have central lung lesions involving major blood vessels
• Patients who require anticoagulant therapy.
• Patients with active epilepsy seizure or symptoms, with brain metastases requiring treatment, with spinal cord compression and with carcinomatous meningitis.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Axitinib

Experimental group

Treatment:

Drug: Axitinib (AG-013736)